Similar articles

• Primary percutaneous coronary intervention for acute MI: improving access and outcomes.

  Karha J, Hook MA, Brener SJ. Karha J, et al. Cleve Clin J Med. 2005 Jul;72(7):559-60, 562, 565-6 passim. doi: 10.3949/ccjm.72.7.559. Cleve Clin J Med. 2005. PMID: 16044653 Review.
• Comparison of angioplasty with stenting in acute myocardial infarction.

  Herrmann HC. Herrmann HC. N Engl J Med. 2002 Aug 1;347(5):367-8; author reply 367-8. doi: 10.1056/NEJM200208013470515. N Engl J Med. 2002. PMID: 12151478 No abstract available.
• Pharmacological facilitation of coronary intervention in ST-segment elevation myocardial infarction: time is of the essence.

  Gersh BJ, Stone GW. Gersh BJ, et al. JACC Cardiovasc Interv. 2010 Dec;3(12):1292-4. doi: 10.1016/j.jcin.2010.08.024. JACC Cardiovasc Interv. 2010. PMID: 21232724 No abstract available.
• Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.

  Sibbing D, Bernlochner I, Schulz S, Massberg S, Schömig A, Mehilli J, Kastrati A. Sibbing D, et al. J Am Coll Cardiol. 2012 Jul 31;60(5):369-77. doi: 10.1016/j.jacc.2012.02.044. Epub 2012 Jun 6. J Am Coll Cardiol. 2012. PMID: 22682553 Clinical Trial.
• Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.

  De Luca G, Suryapranata H, Grimaldi R, Chiariello M. De Luca G, et al. QJM. 2005 Sep;98(9):633-41. doi: 10.1093/qjmed/hci097. Epub 2005 Jul 22. QJM. 2005. PMID: 16040669 Review.